

Australia's Anataara and Microba to find therapeutic treatment for IBS-D

23 August 2021 | News

Clinical trial leverage precision microbiome analysis for Irritable Bowel Syndrome (IBS)-D, a diarrhea prominent subtype of the condition which currently has no definitive cure



Australia-based precision microbiome science company, Microba Life Sciences, will work with Anataara Life Sciences to complete microbiome analysis for a much-needed therapeutic treatment for sufferers of Irritable Bowel Syndrome (IBS)-D.

Anataara have commenced recruitment for a phase 1/2 clinical trial of their Gastrointestinal Re-Programming complementary medicine (GaRP) to address an unmet clinical need for IBS-D.

Microba will apply its high-resolution gut microbiome analysis platform to measure the effect of the treatment on the microbiome by comparing pre-treatment specimens and specimens taken after eight weeks on the GaRP complementary medicine.

One of Anataara's mechanisms of action addresses dysbiosis (microbiome disruption) to rebalance a healthy microbiome for sufferers of this condition. The trial would evaluate the safety and efficacy of GaRP for future use as complementary medicine for sufferers of IBS-D.

Microba's Head of Research Partnerships, Dr Kylie Ellis said that the project was a step forward in addressing an unmet clinical need for IBS-D sufferers.

Anataara CEO Steven Lydeamore said "There is a major unmet need and significant market opportunity for evidence-based complementary medicine for IBS. Anataara's GaRP has demonstrated that it has the potential to manage the devastating symptoms experienced by IBD and IBS patients, by addressing processes that contribute to the pathophysiology of these chronic bowel conditions."

Lydeamore explained that current pharmaceutical treatments had high failure rates and severe side-effects, leading to more than half of IBS and IBD patients trying complementary and alternative medicines (CAMS) in the hope of effectively managing their chronic bowel condition.